Max Masucci
Stock Analyst at TD Cowen
(0.20)
# 4,138
Out of 4,842 analysts
23
Total ratings
16%
Success rate
-31.44%
Average return
Main Sectors:
Stocks Rated by Max Masucci
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BRKR Bruker | Maintains: Hold | $74 → $72 | $36.96 | +94.81% | 1 | Aug 7, 2024 | |
| BLFS BioLife Solutions | Maintains: Outperform | $29 → $25 | $22.39 | +11.66% | 1 | Aug 9, 2023 | |
| GH Guardant Health | Maintains: Outperform | $70 → $53 | $38.19 | +38.78% | 1 | Feb 24, 2023 | |
| HOLX Hologic | Maintains: Outperform | $86 → $95 | $63.71 | +49.11% | 2 | Feb 2, 2023 | |
| QTRX Quanterix | Downgrades: Market Perform | $38 → $18 | $5.29 | +240.26% | 2 | Aug 9, 2022 | |
| BDSX Biodesix | Initiates: Outperform | n/a | $0.34 | - | 2 | Apr 20, 2022 | |
| EVO Evotec SE | Initiates: Outperform | n/a | $3.96 | - | 1 | Nov 29, 2021 | |
| NAUT Nautilus Biotechnology | Initiates: Outperform | n/a | $0.74 | - | 1 | Nov 2, 2021 | |
| MXCT MaxCyte | Initiates: Outperform | n/a | $2.27 | - | 1 | Aug 24, 2021 | |
| CTKB Cytek Biosciences | Initiates: Outperform | n/a | $2.48 | - | 1 | Aug 17, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $3.26 | - | 1 | Aug 9, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $5.80 | - | 1 | Jul 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $25 | $1.22 | +1,949.18% | 1 | May 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $460 → $470 | $84.43 | +456.67% | 4 | Apr 28, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $25 | $6.64 | +276.51% | 1 | Apr 15, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $120 → $145 | $58.08 | +149.66% | 2 | Oct 28, 2020 |
Bruker
Aug 7, 2024
Maintains: Hold
Price Target: $74 → $72
Current: $36.96
Upside: +94.81%
BioLife Solutions
Aug 9, 2023
Maintains: Outperform
Price Target: $29 → $25
Current: $22.39
Upside: +11.66%
Guardant Health
Feb 24, 2023
Maintains: Outperform
Price Target: $70 → $53
Current: $38.19
Upside: +38.78%
Hologic
Feb 2, 2023
Maintains: Outperform
Price Target: $86 → $95
Current: $63.71
Upside: +49.11%
Quanterix
Aug 9, 2022
Downgrades: Market Perform
Price Target: $38 → $18
Current: $5.29
Upside: +240.26%
Biodesix
Apr 20, 2022
Initiates: Outperform
Price Target: n/a
Current: $0.34
Upside: -
Evotec SE
Nov 29, 2021
Initiates: Outperform
Price Target: n/a
Current: $3.96
Upside: -
Nautilus Biotechnology
Nov 2, 2021
Initiates: Outperform
Price Target: n/a
Current: $0.74
Upside: -
MaxCyte
Aug 24, 2021
Initiates: Outperform
Price Target: n/a
Current: $2.27
Upside: -
Cytek Biosciences
Aug 17, 2021
Initiates: Outperform
Price Target: n/a
Current: $2.48
Upside: -
Aug 9, 2021
Initiates: Outperform
Price Target: n/a
Current: $3.26
Upside: -
Jul 20, 2021
Initiates: Outperform
Price Target: n/a
Current: $5.80
Upside: -
May 11, 2021
Initiates: Buy
Price Target: $25
Current: $1.22
Upside: +1,949.18%
Apr 28, 2021
Maintains: Buy
Price Target: $460 → $470
Current: $84.43
Upside: +456.67%
Apr 15, 2021
Initiates: Buy
Price Target: $25
Current: $6.64
Upside: +276.51%
Oct 28, 2020
Maintains: Buy
Price Target: $120 → $145
Current: $58.08
Upside: +149.66%